newsfilter
← Latest News
Business Wire·

Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer

First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch expected by year-end, pending final reimbursement and pricing Natera,